It is estimated that more than one-third of American adults and about 17% of adolescents are obese. The health effects of obesity are myriad and include the development of type 2 diabetes, hypertension, cardiovascular disease, cancer, high blood pressure, and sleep apnea. Obesity and its sequelae are estimated to generate $147 billion in health care costs in the US alone. The complexity involved in managing obesity may affect both patient candidacy for certain treatment options as well as adherence to lifestyle changes necessary to sustain weight loss and improve health outcomes. Clinical interest is therefore high in treatments that may be used for patients at multiple levels of obesity, as well as in interventions that promote better adherence to lifestyle change.

For questions or additional information, please contact info@icer.org.

Interventions of interest, May 2015:

Devices
Temporary intragastric balloon systems (e.g., Silimed®, ReShape®)
• Vagus nerve block devices (e.g., Maestro® system)
• Duodenal-jejunal bypass liner (EndoBarrier®)


Medications
• Naltrexone/bupropion sustained-release (Contrave®)
• Phentermine/topiramate extended-release (Qsymia®)
• Lorcaserin (Belviq®)
• Liraglutide (Saxenda®)

Intervention of interest, April 2015:

  • Roux-en-Y gastric bypass (RYGB)
  • Biliopancreatic diversion/duodenal switch (BPD/DS)
  • Laparoscopic adjustable gastric banding (LAGB)
  • Vertical sleeve gastrectomy (VSG)


Final Documents

Below you will find the final documents from the assessment review process: